Cogent Biosciences COGT
NASDAQ COGT
$32.52 +0.86 (+2.72%)
As of: Sep 30, 2026 · 3:53 PM EDT

Cogent Biosciences (COGT) Debt Ratio (2025)

Updated

Cogent Biosciences' Debt Ratio came in at 0.10 for Q3 2025, down 35.0% from the prior quarter.

Analysis

Cogent Biosciences (COGT) Debt Ratio (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 0.24
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 0.52
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 0.42
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 0.31
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 0.00
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 0.60
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Cogent Biosciences 5.43 Bn 5.43 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 0.10
Jun 30, 2025 0.16
API Access

Cogent Biosciences Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=COGT&period=max&api_key=YOUR_API_KEY